Globhy
AllBusinessHealthMarketingTechnologyTravelUncategorized
Posted on 14 Oct 2026Edited on 14 Oct 2026

Share:

Menaquinone-7 CAS 2124-57-4: Understanding FermaQuin K2 MK-7 for Nutraceutical Manufacturing

Menaquinone-7 CAS 2124-57-4: Understanding FermaQuin K2 MK-7 for Nutraceutical Manufacturing

Menaquinone-7 CAS 2124-57-4 is an important identifier for Vitamin K2 MK-7, an ingredient used in nutritional formulations associated with vitamin K-dependent biological processes.

The demand for high-quality Vitamin K2 ingredients is increasing as nutraceutical manufacturers seek reliable solutions for bone health, cardiovascular wellness, and specialized nutritional formulations. Among the different forms of Vitamin K2, menaquinone-7 (MK-7) has gained considerable attention because of its relatively long half-life and role in activating vitamin K-dependent proteins. For manufacturers and ingredient procurement teams, understanding its production methods, quality characteristics, and formulation requirements is essential when selecting a suitable ingredient.

Menaquinone-7 CAS 2124-57-4 is the chemical identifier associated with menaquinone-7, commonly known as Vitamin K2 MK-7. FermaQuin K2 MK-7 from Fermbox Bio is a fermentation-derived ingredient developed using controlled microbial fermentation, purification, and quality-focused manufacturing processes. This approach is designed to support high purity, batch-to-batch consistency, and reliable ingredient supply for nutraceutical applications.

What Is Menaquinone-7 CAS 2124-57-4?

Menaquinone-7 is a member of the vitamin K family and is commonly abbreviated as MK-7. It is a fat-soluble compound involved in vitamin K-dependent biological processes. The compound is particularly relevant to nutritional formulations because vitamin K supports the activation of specific proteins associated with normal blood coagulation and bone metabolism.

The identifier Menaquinone-7 CAS 2124-57-4 helps manufacturers, researchers, procurement specialists, and regulatory teams identify the specific chemical substance when reviewing technical documents, ingredient specifications, and sourcing requirements.

MK-7 is distinguished from other menaquinones by the length of its side chain. Compared with menaquinone-4 (MK-4), MK-7 generally has a longer half-life in the body, allowing it to remain available in circulation for a longer period. This characteristic makes it an important ingredient to consider when developing Vitamin K2 supplements and combination nutritional products.

However, the suitability of an ingredient for a finished product depends on its purity, stability, formulation compatibility, intended use, and applicable regulatory requirements.

FermaQuin K2 MK-7: A Precision-Fermentation Approach

FermaQuin K2 MK-7 from Fermbox Bio is produced through controlled microbial fermentation. The manufacturing approach is designed to produce all-trans menaquinone-7, followed by purification and quality control to achieve the required ingredient specifications.

Precision fermentation provides a controlled production environment in which relevant manufacturing parameters can be monitored throughout the process. This approach can help manufacturers manage production variability and establish repeatable quality specifications.

The production process can be understood through three primary stages.

1. Controlled Fermentation

The process begins with microbial fermentation under controlled conditions. Renewable feedstocks are used in the production platform to support the fermentation process, which produces the target MK-7 compound.

Monitoring critical process parameters is important for maintaining reproducibility and supporting consistent manufacturing performance.

2. Purification and Ingredient Processing

Following fermentation, the target compound undergoes extraction and purification. These stages are designed to achieve the required purity and quality characteristics while managing impurities and the final ingredient profile.

Purification is particularly important for nutraceutical ingredients because manufacturers need documented specifications before incorporating an ingredient into a finished formulation.

3. Formulation and Quality Control

After purification, the ingredient can be processed into suitable delivery formats, including powder and oil. Analytical verification and quality release procedures help assess whether the finished ingredient meets its established specifications.

For manufacturers sourcing FermaQuin K2 MK-7, reviewing the applicable certificate of analysis, purity data, stability information, and technical documentation is an important part of ingredient qualification.

Why All-Trans MK-7 Matters in Ingredient Selection

Menaquinone-7 can exist in different geometric isomeric forms. The all-trans form is an important consideration when evaluating Vitamin K2 MK-7 ingredients for nutraceutical applications.

An ingredient's isomer profile can influence how it is characterised and assessed against manufacturing specifications. Therefore, procurement and formulation teams should review analytical documentation that identifies the MK-7 profile and confirms compliance with the required specifications.

FermaQuin focuses on all-trans MK-7 through controlled fermentation and purification. This quality-focused approach is intended to support the development of nutraceutical formulations that require a defined ingredient profile.

Share:

More in Uncategorized

View category
Global Demand for Advanced Fracture Fixation Solutions Supports Market Expansion
Uncategorized
3

Global Demand for Advanced Fracture Fixation Solutions Supports Market Expansion

The global internal trauma fixation device market size was valued at USD 11.71 billion in 2025 and is projected to grow from USD 12.32 billion in 2026 to USD 18.48 billion by 2034, registering a CAGR of 5.2% during the forecast period from 2026 to 2034. North America dominated the internal trauma fixation device market with a market share of 38.2% in 2025.

READ ARTICLE
Semiconductor Advancements Support Innovation in Satellite Commercial-Off-the-Shelf Components
Uncategorized
4

Semiconductor Advancements Support Innovation in Satellite Commercial-Off-the-Shelf Components

The global satellite commercial-off-the-shelf components market size was valued at USD 2021.05 million in 2025 and is projected to grow from USD 2045.30 million in 2026 to USD 2250.10 million by 2034, registering a CAGR of 1.2% during the forecast period from 2026 to 2034. North America dominated the satellite commercial-off-the-shelf components market with a market share of 45.32% in 2025.

READ ARTICLE